GLP-1 Therapy and OSA: Promise, But Limits

https://www.medscape.com/viewarticle/glp-1-therapy-and-osa-promise-limits-2026a1000yb1?ecd=WNL_trdalrt_pos1_ous_260918_etid8704513&uac=148436CN&impID=8704513 Targeting obesity could benefit a large proportion of patients with obstructive sleep apnea (OSA). GLP-1 receptor agonist (RA)-based treatments offer a promising therapeutic approach, but the phenotypes that respond best — either alone or in combination with continuous positive airway pressure (CPAP) — still need to be identified to enable personalized care. The update was presented in 2026 at the European Respiratory Society Congress in Barcelona, Spain.